Precision medicine

Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven Precision Medicine for Gastroenterology

Retrieved on: 
Tuesday, August 3, 2021
Health, Other Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Evidence-based medicine, Precision medicine, Systems biology, ITERATIVE SCOPES, OBVIOUS VENTURES

Iterative Scopes, a pioneering company aiming to bring cutting-edge precision medicine to gastroenterology, today disclosed that it has closed a $30 million Series A financing.

Key Points: 
  • Iterative Scopes, a pioneering company aiming to bring cutting-edge precision medicine to gastroenterology, today disclosed that it has closed a $30 million Series A financing.
  • For a variety of reasons, gastroenterology has seen fewer benefits from precision medicine tools than other serious illnesses such as oncology and infectious diseases.
  • As part of the financing, Nan Li, Managing Director at Obvious Ventures, will also join Iterative Scopes board of directors.
  • Iterative Scopes has developed world-class AI capabilities to accelerate the industry towards drastically improved clinical decision-making and ultimately precision medicine.

Burning Rock Schedules Second Quarter of 2021 Earnings Release on August 31, 2021

Retrieved on: 
Monday, August 2, 2021
Communication, Forward-looking statement, NGS, Precision medicine, Articles

Please visit the companys investor relations website at https://ir.brbiotech.com/news-events/news-releases on August 31, 2021 to view the earnings release prior to the conference call.

Key Points: 
  • Please visit the companys investor relations website at https://ir.brbiotech.com/news-events/news-releases on August 31, 2021 to view the earnings release prior to the conference call.
  • Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.
  • For more information about Burning Rock, please visit: www.brbiotech.com .
  • Statements that are not historical facts, including statements about Burning Rocks beliefs and expectations, are forward-looking statements.

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

Retrieved on: 
Monday, August 2, 2021
Biotechnology, General Health, Hospitals, Health, Pharmaceutical, Branches of biology, Biology, Life sciences, Glycoproteomics, Proteomics, Biomarkers, Biotechnology, Chemical pathology, Medical signs, Precision medicine

InterVenn Biosciences today announced the completion of a $201 million Series C financing.

Key Points: 
  • InterVenn Biosciences today announced the completion of a $201 million Series C financing.
  • To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications.
  • InterVenn Biosciences utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine.
  • For more information about InterVenn Biosciences, please visit the companys website .

Pillar Biosciences Appoints Dr. Eric Lai to its Board of Directors

Retrieved on: 
Monday, August 2, 2021
Hardware, FDA, Data management, Technology, Pharmaceutical, Surgery, Physical therapy, Oncology, Medical devices, Genetics, Biotechnology, Science, Software, Other Science, Research, Health, Branches of biology, Biology, Life sciences, Biotechnology, Molecular diagnostics, Precision medicine, Massive parallel sequencing, DNA sequencing

Pillar Biosciences , an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Eric Lai, Ph.D. to the Board of Directors.

Key Points: 
  • Pillar Biosciences , an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Eric Lai, Ph.D. to the Board of Directors.
  • Dr. Lai brings more than 20 years of experience in drug and IVD molecular diagnostic development to the team at Pillar Biosciences.
  • I am excited to join the Board at Pillar Biosciences, to support the advancement of high-quality oncology diagnostic testing to enable precision medicine as the first option for every patient, said Dr. Eric Lai, Board Member, Pillar Biosciences.
  • Eric brings invaluable expertise to our team at Pillar, as we work to increase access to precision medicine, said Gang Song, Ph.D., Founder and CEO at Pillar Biosciences.

Seasoned Data Science Leader Named President and CEO of M2GEN

Retrieved on: 
Monday, August 2, 2021
Health informatics, Johnson & Johnson, Companies, Health care, Life sciences

Mr. Gabriele is a seasoned entrepreneur and data science leader who most recently served as Senior Vice President and Chief Strategy & Data Science Officer, Medical Devices Sector, at Johnson & Johnson.

Key Points: 
  • Mr. Gabriele is a seasoned entrepreneur and data science leader who most recently served as Senior Vice President and Chief Strategy & Data Science Officer, Medical Devices Sector, at Johnson & Johnson.
  • Most recently, as Senior Vice President and Chief Strategy & Data Science Officer for Medical Devices at Johnson & Johnson, he led global strategy development, pricing strategy, data science, data strategy, digital customer experience and business insights.
  • Prior to that, he held senior strategy and data science roles in the Johnson & Johnson Pharmaceutical organization.
  • M2GEN is an oncology-focused health informatics solutions company advancing precision medicine and transforming cancer carethrough clinical and molecular data.

Azzur Labs Strengthens National Foothold with New Leadership and Testing Capabilities in Chicago and Raleigh

Retrieved on: 
Monday, August 2, 2021

Cecil Runyon brings to Azzur Labs more than 17 years of experience and will oversee all operations and client relations for the Chicago operation.

Key Points: 
  • Cecil Runyon brings to Azzur Labs more than 17 years of experience and will oversee all operations and client relations for the Chicago operation.
  • Prior to joining Azzur Labs, Cecil spent several years in the pharmaceutical, medical device, and cosmetic industries.
  • Jorge brings to Azzur Labs Raleigh more than 15 years of experience in cell and molecular biology.
  • "Azzur Labs is excited to welcome both Cecil and Jorge as leaders on our team," said Kym Faylor , President of Azzur Labs.

Scipher Medicine Increases Patient Access for Prismra® by Expanding Intended Use in Autoimmune Patients

Retrieved on: 
Thursday, July 29, 2021
Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Connective tissue diseases, Arthritis, Rheumatoid arthritis, Precision medicine, Sjögren syndrome, Autoimmunity, Lars Klareskog

WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.

Key Points: 
  • WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA blood test.
  • PrismRA is a first-of-its-kind molecular signature test that informs personalized treatment decisions for RA patients at any point in the clinical journey.
  • PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.
  • We partner with payers, providers, and pharma along the healthcare value chain to bring precision medicine to autoimmune diseases.

Tempus Unveils Its Scalable Tumor Organoid Screening Platform In Cell Reports Study

Retrieved on: 
Wednesday, July 28, 2021
Oncology, Health, Technology, Surgery, Other Technology, Software, Biotechnology, Branches of biology, Biology, Natural sciences, Stem cells, Organoid, Tissue engineering, Assay, Precision medicine, Cerebral organoid

Tempus , a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform.

Key Points: 
  • Tempus , a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform.
  • Given the scale of Tempus organoid program, it now houses one of the largest repositories of these models in the world.
  • Overall, the Tempus organoids accurately represented patients tumor DNA mutational profiles, RNA expression, and structural genomic features.
  • Lastly, the study presents a neural network-based, universal solid tumor therapeutic profiling assay predicting organoid viability from simple light microscopy, reducing cost and time in high-throughput screening.

Lirio Launches Precision Nudging™ Solution for Well Visit Adherence

Retrieved on: 
Wednesday, July 28, 2021
Health sciences, Health, Evidence-based medicine, Precision medicine, Systems biology, Lirio, Adherence, Personalization

KNOXVILLE, Tenn.and NASHVILLE, Tenn., July 28, 2021 /PRNewswire/ -- Lirio,whose Precision Nudging solution promotes health throughAI-poweredbehavior change, today announced the launch of a new Precision Nudging solution to encourage people to schedule and attend well visit appointments with their healthcare providers.

Key Points: 
  • KNOXVILLE, Tenn.and NASHVILLE, Tenn., July 28, 2021 /PRNewswire/ -- Lirio,whose Precision Nudging solution promotes health throughAI-poweredbehavior change, today announced the launch of a new Precision Nudging solution to encourage people to schedule and attend well visit appointments with their healthcare providers.
  • The solution was co-developed with Rochester Regional Health (RRH) in New York to encourage more women to follow recommended well visit schedules.
  • Early R&D results of the Precision Nudging solution demonstrate that Lirio's approach to personalization drives up to six times greater well visit adherence and is particularly effective with hard-to-engage populations such as racial minorities and low-income households.
  • Like precision medicine's individualized treatment plans, Precision Nudging allows Lirio to apply tailored behavioral interventions to overcome person-specific barriers to action.

Novigenix Wins the 2021 Felix Burda Award in Medicine & Science

Retrieved on: 
Thursday, July 22, 2021
Colorectal cancer, Felix Burda Foundation, Precision medicine, Cancer, Health, Medicine, Medical specialties, Hubert Burda

LAUSANNE, Switzerland, July 22, 2021 /PRNewswire/ -- Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced that it has been awarded the 2021 Felix Burda Award in the Medicine & Science category.

Key Points: 
  • LAUSANNE, Switzerland, July 22, 2021 /PRNewswire/ -- Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced that it has been awarded the 2021 Felix Burda Award in the Medicine & Science category.
  • The Felix Burda Award was created in 2003 in Munich, Germany by the Felix Burda Foundation tohonor individuals and teams having made outstanding contributions to the prevention and early detection of colorectal cancer.
  • The foundation has established an independent Jury of leading figures from academia and medical practice to preside over evaluation of nominations and selection of winner of the Award in the Medicine & Science category.
  • Novigenix is a precision medicine biotech providing a new understanding of the human host immune response to cancer.